Jazz Pharmaceuticals (JAZZ) Total Current Liabilities (2010 - 2026)

Jazz Pharmaceuticals has reported Total Current Liabilities for 17 years, with the latest figure at $2.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 83.75% year-over-year to $2.2 billion; the trailing twelve-month figure through Mar 2026 stood at $2.2 billion (up 83.75% YoY), and the FY2025 full-year result was $2.2 billion, up 115.92% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $2.2 billion, roughly flat from $2.2 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $2.3 billion in Q3 2025, with the low at $705.4 million in Q2 2022.
• Average Total Current Liabilities over 5 years is $1.4 billion, with a median of $1.2 billion recorded in 2025.
• Year-over-year, Total Current Liabilities sank 34.54% in 2024 and surged 120.79% in 2025.
• Tracing JAZZ's Total Current Liabilities over 5 years: stood at $933.2 million in 2022, then soared by 64.67% to $1.5 billion in 2023, then tumbled by 32.42% to $1.0 billion in 2024, then surged by 115.92% to $2.2 billion in 2025, then gained by 0.18% to $2.2 billion in 2026.
• The last three Total Current Liabilities figures came in at $2.2 billion (Q1 2026), $2.2 billion (Q4 2025), and $2.3 billion (Q3 2025), per Business Quant data.

Peer Comparison